No House member has disclosed a NEOG trade since 2025.
From the House's STOCK Act reports (Senate not included). Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Aug 13, 2026 | Stacey Jennifer EvansOfficer | Stock Award(Grant) at price 11.65 per share. | 38.6K | $450.00K |
| Aug 13, 2026 | Riggsbee Richard BryanChief Financial Officer | Stock Award(Grant) at price 11.65 per share. | 51.5K | $600.00K |
| Aug 13, 2026 | Ranalli Tamara AOfficer | Stock Award(Grant) at price 11.65 per share. | 25.8K | $300.00K |
| Aug 13, 2026 | Nassif MikhealChief Executive Officer | Stock Award(Grant) at price 11.65 per share. | 141.6K | $1.65M |
| Aug 3, 2026 | Nassif MikhealChief Executive Officer | Purchase at price 11.81 per share. | 370 | $4.37K |
| May 17, 2026 | Rocklin Amy MFormer | Conversion of Exercise of derivative security at price 9.29 per share. | 35.2K | $326.85K |
| May 3, 2026 | Moylan John PatrickOfficer | Conversion of Exercise of derivative security at price 9.53 per share. | 4.6K | $43.44K |
| Apr 30, 2026 | Stacey Jennifer EvansOfficer | Stock Award(Grant) at price 9.53 per share. | 39.3K | $375.00K |
| Feb 16, 2026 | Nassif MikhealChief Executive Officer | Purchase at price 10.94 per share. | 23 | $252 |
| Feb 1, 2026 | Nassif MikhealChief Executive Officer | Purchase at price 9.86 - 10.00 per share. | 49 | $486 |
| Jan 15, 2026 | Nassif MikhealChief Executive Officer | Purchase at price 9.33 per share. | 137 | $1.28K |
| Jan 6, 2026 | Ranalli Tamara AOfficer | Stock Award(Grant) at price 7.38 per share. | 50.8K | $375.00K |
| Jan 6, 2026 | Ranalli Tamara AOfficer | Stock Award(Grant) at price 7.38 per share. | 101.6K | $750.00K |
| Nov 30, 2025 | Naemura David HartmanFormer | Conversion of Exercise of derivative security at price 5.98 per share. | 12.9K | $77.21K |
| Nov 2, 2025 | Nassif MikhealChief Executive Officer | Purchase at price 6.25 per share. | 177 | $1.11K |
| Nov 2, 2025 | Riggsbee Richard BryanChief Financial Officer | Stock Award(Grant) at price 6.29 per share. | 178.9K | $1.12M |
| Oct 26, 2025 | Rodriguez Rafael ADirector | Conversion of Exercise of derivative security at price 6.19 per share. | 1.8K | $11.00K |
| Oct 26, 2025 | Borel James C.Director | Conversion of Exercise of derivative security at price 6.19 per share. | 2K | $12.54K |
| Oct 26, 2025 | Borel James C.Director | Conversion of Exercise of derivative security at price 6.19 per share. | 1.8K | $11.00K |
| Oct 26, 2025 | Green Ronald DDirector | Conversion of Exercise of derivative security at price 6.19 per share. | 1.8K | $11.00K |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 46.2 | 9.9 | -17.3 | 1.2 | -4.6 | 0.2 | 33.9 | -4.0 | 10.7 | -6.3 | +71.7% | ||
| 2025 | -5.6 | -12.3 | -13.7 | -41.8 | 16.0 | -18.4 | -2.7 | 23.7 | -0.7 | 8.1 | -3.1 | 16.9 | −42.4% |
| 2024 | -22.9 | 10.9 | -8.2 | -21.9 | 6.7 | 18.9 | 9.0 | 1.3 | -2.6 | -15.1 | -0.7 | -14.4 | −39.6% |
| 2023 | 40.6 | -17.4 | 4.7 | -7.0 | 1.6 | 24.4 | 6.6 | -0.3 | -19.8 | -19.7 | 14.0 | 18.5 | +32.0% |
| 2022 | -19.7 | -2.1 | -13.6 | -14.4 | 0.2 | -9.0 | -4.0 | -9.6 | -33.2 | -5.5 | 25.5 | -8.0 | −66.5% |
| 2021 | 2.0 | 1.3 | 8.5 | 8.0 | -3.9 | -0.2 | -5.4 | 0.5 | -0.8 | -2.6 | -5.2 | 13.2 | +14.5% |
| 2020 | 3.1 | -9.7 | 10.3 | -6.6 | 13.8 | 9.0 | -1.1 | -0.7 | 2.7 | -10.9 | 6.4 | 6.8 | +21.5% |
| 2019 | 6.9 | 1.7 | -7.4 | 5.7 | -7.1 | 10.2 | 15.0 | -1.2 | -3.4 | -4.5 | 2.3 | -2.0 | +14.5% |
| 2018 | -4.3 | -1.3 | 15.0 | 1.7 | 11.1 | 5.9 | 2.8 | 13.4 | -23.4 | -15.1 | 6.8 | -12.1 | −7.6% |
| 2017 | 0.1 | -1.8 | 1.1 | -4.9 | 1.5 | 9.2 | -4.7 | 4.6 | 12.4 | 3.5 | 4.6 | -2.0 | +24.6% |
| 2016 | -7.7 | -5.6 | 2.2 | -6.2 | 4.5 | 13.9 | -2.0 | 7.1 | -5.3 | -5.8 | 20.1 | 4.3 | +16.8% |
| 2015 | -7.0 | 11.0 | -8.6 | -4.7 | 4.9 | 1.5 | 22.7 | -11.3 | -12.9 | 20.1 | 9.3 | -4.3 | +14.0% |
| 2014 | -8.1 | 3.1 | 3.8 | -7.1 | -9.6 | 7.1 | 7.9 | -3.6 | -6.2 | 11.1 | 0.9 | 11.9 | +8.5% |
| 2013 | 2.6 | 0.7 | 5.9 | 2.5 | 7.2 | 2.0 | 1.7 | -4.2 | 12.2 | 14.2 | 10.1 | -10.2 | +51.3% |
| 2012 | 6.3 | 6.5 | 12.6 | -0.2 | -0.1 | 18.6 | -16.7 | 1.5 | 9.4 | 0.2 | 6.5 | -0.5 | +47.9% |
| 2011 | -12.4 | 4.0 | 10.7 | 1.3 | 7.0 | 0.8 | -8.5 | -16.1 | 0.1 | 11.3 | -8.8 | -13.0 | −25.3% |
| 2010 | -10.0 | 14.0 | 3.6 | 4.9 | -2.4 | 1.3 | 14.6 | -2.1 | 15.8 | -1.3 | 11.2 | 10.4 | +73.8% |
| 2009 | 4.8 | -18.8 | 2.7 | 3.8 | -2.8 | 31.5 | 0.6 | -3.9 | 15.3 | -1.8 | 2.6 | 8.8 | +41.8% |
| 2008 | -9.6 | 12.5 | -7.0 | 0.1 | 4.8 | -13.1 | 20.0 | -5.1 | 8.1 | 4.6 | -23.3 | 10.6 | −5.9% |
| 2007 | 2.7 | 0.3 | 2.8 | 6.8 | 9.1 | 5.0 | 1.6 | 8.9 | 11.4 | 12.7 | -0.4 | 0.2 | +79.4% |
Neogen Corporation develops, manufactures, and markets various products and services for food and animal safety in the United States and internationally. It operates through Food Safety and Animal Safety segments. The company offers diagnostic test kits and complementary products to detect dangerous and/or unintended substances in human food and animal feed, such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns. It also provides reagents and test kits used in immunoassay production, forensic and animal toxicology, and life science research; unique colorimetric and chemiluminescent substrates for research use; veterinary instruments and delivery systems under the Ideal and Prima Tech brands; and precision instruments designed for injections, topical and oral administration, artificial insemination, and animal identification for farmers, ranchers, and veterinarian under the Prima Tech brand. In addition, the company offers digestive aids and nutritional supplements; Natural Vitamin E-AD to address vitamin deficiencies in swine, cattle, and sheep; RenaKare; companion animal parasiticides under Provecta brand; BotVax B; EqStim; ImmunoRegulin; companion animal parasiticides under the Provecta brand; rodent and insect control products under the Ramik, CyKill, Havoc, Prozap, SureKill, and StandGuard brands. Further, it markets Uniprim, a veterinary antibiotic; operates sgenomics labs offering DNA genotyping, sequencing, and trait analysis for livestock and companion animals; and provides software systems that help testers to analyze and store results and perform analysis. The company has a strategic collaboration with Hinalea Imaging Corp. to develop digital imaging solutions for food safety and quality inspection. Neogen Corporation was incorporated in 1981 and is headquartered in Lansing, Michigan.
Buy / hold / sell counts